Quantum BioPharma Announces Update to Previously Announced Private Placement
Quantum BioPharma (NASDAQ: QNTM) has announced updates regarding its previously disclosed non-brokered private placement. The company will seek shareholder approval for the offering of class A multiple voting shares (MVS) at its upcoming annual general meeting on September 26, 2025. The private placement aims to raise gross proceeds of up to $600.
The offering is expected to be primarily subscribed by existing MVS holders and will include a statutory hold period of four months plus one day. The proceeds will be used for general working capital purposes. The securities being offered will not be registered under the U.S. Securities Act of 1933 and cannot be sold in the United States without registration or exemption.
["Company is raising additional working capital through private placement", "Existing MVS holders expected to participate, showing continued investor confidence"]Quantum BioPharma (NASDAQ: QNTM) ha comunicato aggiornamenti sul collocamento privato non intermediato precedentemente annunciato. La societ脿 chieder脿 l'approvazione degli azionisti per l'emissione di azioni di classe A con diritto di voto multiplo (MVS) alla sua assemblea generale annuale del 26 settembre 2025. Il collocamento privato punta a raccogliere proventi lordi fino a $600.
L'offerta dovrebbe essere sottoscritta principalmente dagli attuali detentori di MVS e preveder脿 un periodo di blocco legale di quattro mesi pi霉 un giorno. I proventi saranno utilizzati per il capitale circolante generale. I titoli offerti non saranno registrati ai sensi del U.S. Securities Act del 1933 e non potranno essere venduti negli Stati Uniti senza registrazione o esenzione.
La societ脿 mira a rafforzare il capitale circolante tramite questo collocamento; la prevista partecipazione degli attuali detentori di MVS indica una fiducia continuativa da parte degli investitori.
Quantum BioPharma (NASDAQ: QNTM) anunci贸 actualizaciones sobre la colocaci贸n privada no intermediada previamente divulgada. La compa帽铆a solicitar谩 la aprobaci贸n de los accionistas para la emisi贸n de acciones Clase A con voto m煤ltiple (MVS) en su junta general anual del 26 de septiembre de 2025. La colocaci贸n privada busca recaudar ingresos brutos por hasta $600.
Se espera que la oferta sea suscrita principalmente por los actuales titulares de MVS y que incluya un per铆odo de retenci贸n legal de cuatro meses m谩s un d铆a. Los fondos se destinar谩n a capital de trabajo general. Los valores ofrecidos no estar谩n registrados conforme al U.S. Securities Act de 1933 y no podr谩n venderse en los Estados Unidos sin registro o una exenci贸n.
La operaci贸n pretende reforzar el capital de trabajo; la participaci贸n prevista de los titulares actuales de MVS refleja la confianza sostenida de los inversores.
Quantum BioPharma (NASDAQ: QNTM)電� 鞚挫爠鞐� 瓿奠嫓頃� 欷戧皽鞚� 牍勱磤鞐槙 靷 氚滍枆鞐� 雽�頃� 斓滌嫚 雮挫毄鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2025雲� 9鞗� 26鞚� 鞓堨爼霅� 鞐半 欤检＜齑濏殞鞐愳劀 A旮� 雼れ 鞚橁舶甓� 欤检嫕(MVS) 氚滍枆鞐� 雽�頃� 欤检＜ 鞀轨澑鞚� 鞖旍箔頃� 鞓堨爼鞛呺媹雼�. 鞚� 靷 氚滍枆鞚� 斓滊寑 $600鞚� 齑� 臁半嫭鞚� 氇╉憸搿� 頃╇媹雼�.
氚滍枆鞚� 欤茧 旮办〈 MVS 氤挫湢鞛愱皜 觳暯頃� 瓴冹溂搿� 鞓堨儊霅橂┌, 氩曥爼 氤挫湢旮瓣皠鞚� 4臧滌洈 氚� 1鞚检澊 鞝侅毄霅╇媹雼�. 臁半嫭 鞛愱笀鞚� 鞚茧皹 鞖挫榿鞛愱笀鞙茧 靷毄霅� 鞓堨爼鞛呺媹雼�. 鞝滌晥霅� 歃濌秾鞚� 1933雲� 氙戈淡 歃濌秾氩�(U.S. Securities Act)鞐� 霌彪霅橃 鞎婌晿鞙茧┌, 霌彪鞚措倶 氅挫牅臧� 鞐嗠姅 頃� 氙戈淡 雮挫棎靹� 韺愲Г霅� 靾� 鞐嗢姷雼堧嫟.
須岇偓電� 鞚措矆 靷 氚滍枆鞚� 韱淀暣 鞖挫榿鞛愱笀鞚� 氤搓皶頃橂牑 頃橂┌, 旮办〈 MVS 氤挫湢鞛愳潣 鞓堨儊 彀胳棳電� 韴瀽鞛愲摛鞚� 歆�靻嶌爜鞚� 鞁犽毳� 鞁滌偓頃╇媹雼�.
Quantum BioPharma (NASDAQ: QNTM) a annonc茅 des mises 脿 jour concernant son placement priv茅 sans courtier pr茅c茅demment divulgu茅. La soci茅t茅 sollicitera l'approbation des actionnaires pour l'茅mission d'actions de cat茅gorie A 脿 votes multiples (MVS) lors de son assembl茅e g茅n茅rale annuelle du 26 septembre 2025. Le placement priv茅 vise 脿 lever des produits bruts jusqu'脿 $600.
Il est pr茅vu que l'offre soit principalement souscrite par les d茅tenteurs actuels de MVS et qu'elle soit assortie d'une p茅riode de blocage l茅gale de quatre mois plus un jour. Les produits seront utilis茅s pour les besoins g茅n茅raux en fonds de roulement. Les titres offerts ne sont pas enregistr茅s en vertu du U.S. Securities Act de 1933 et ne peuvent 锚tre vendus aux 脡tats-Unis sans enregistrement ou exemption.
La soci茅t茅 cherche ainsi 脿 renforcer son fonds de roulement; la participation attendue des d茅tenteurs actuels de MVS t茅moigne d'une confiance continue des investisseurs.
Quantum BioPharma (NASDAQ: QNTM) hat Aktualisierungen zu der zuvor angek眉ndigten, nicht durch Broker vermittelten Privatplatzierung bekanntgegeben. Das Unternehmen wird auf seiner Hauptversammlung am 26. September 2025 die Zustimmung der Aktion盲re zur Ausgabe von Stammaktien der Klasse A mit Mehrstimmrecht (MVS) einholen. Die Privatplatzierung zielt darauf ab, Bruttoerl枚se von bis zu $600 zu erzielen.
Die Emission soll haupts盲chlich von bestehenden MVS-Inhabern gezeichnet werden und unterliegt einer gesetzlichen Haltefrist von vier Monaten zuz眉glich einem Tag. Die Erl枚se werden f眉r das allgemeine Betriebskapital verwendet. Die angebotenen Wertpapiere sind nicht nach dem U.S. Securities Act von 1933 registriert und d眉rfen in den Vereinigten Staaten ohne Registrierung oder Ausnahme nicht ver盲u脽ert werden.
Das Unternehmen beabsichtigt, sein Betriebskapital durch die Privatplatzierung aufzustocken; die erwartete Beteiligung der bestehenden MVS-Inhaber signalisiert anhaltendes Vertrauen der Investoren.
- None.
- Small offering size of only $600 indicates limited funding
- Additional shareholder approval required, potentially delaying the process
- Restricted trading of securities due to statutory hold period
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross proceeds of up to
The Company expects that the entirety of the Offering will be subscribed for by the existing holders of MVS. The Offering is expected to close on or about September 26, 2025, subject to receiving the requisite shareholder approval at the Meeting. All securities issued pursuant to the Offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. The Company intends to use the proceeds of the Offering for general working capital purposes. For further details on the Offering, including Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions disclosure, refer to the Company's press release dated June 27, 2025.
The Company has filed a material change report more than 21 days before the expected closing of the Offering in accordance with MI 61-101 on its SEDAR+ profile.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
About Quantum BioPharma
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit .
This press release contains certain "forward-looking statements" within the meaning of Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as "believes", "anticipates", "expects", "is expected", "scheduled", "estimates", "pending", "intends", "plans", "forecasts", "targets", or "hopes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "will", "should" "might", "will be taken", or "occur" and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements that address activities, events or developments that the Company expects or anticipates will or may occur in the future, including the Meeting, Offering and subscription to the Offering by insiders of the Company, and anticipated closing date of the Offering.
In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the Company's ability to comply with all applicable regulations and laws, including environmental, health and safety laws; receipt of all regulatory approvals; receipt of shareholder approval; the Meeting proceeding as anticipated; the Company having sufficient working capital for future operating activities; the ability of the Company to achieve its business objectives and milestones and the anticipated timing of execution; the Company's ability to continue as a going concern and the Company's ability to use the proceeds from the Offering for the business objectives outlined herein.
The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: changes in general economic, business and political conditions, including changes in the financial markets; consents or authorizations required; changes in laws, regulations and policies affecting the Company's operations; currency fluctuations; environmental issues and liabilities; the potential impact of the announcement or consummation of the Offering on relationship, including with regulatory bodies, employees, suppliers, customers and competitors; the inability of the Company to obtain additional financing for continued operations on terms acceptable to the Company; the lack of control over the Company's investees; risks relating to investing in the MVS; risks relating to the use of proceeds from the Offering; volatility in the market price of the shares; dilution of shareholders' holdings; negative operating cash flow; the negative effects of interest rate and exchange rate changes; risks relating to the Company's reliance on key employees; limitations in the liquidity of the MVS; the Company's inability to receive shareholder approval of the Offering at the Meeting; litigation risks; the Company's inability to expand into new business areas and geographic markets; management of growth; and the Company's inability to continue as a going concern.
Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at and on the EDGAR section of the SEC's website at for a more complete discussion of such risk factors and their potential effects.
Contacts
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board, Quantum BioPharma Ltd.
Email: [email protected]
Telephone: (416) 854-8884
To view the source version of this press release, please visit
FAQ
When will Quantum BioPharma (QNTM) hold its shareholder meeting for the private placement approval?
How much is Quantum BioPharma (QNTM) planning to raise in its private placement?
Who are the expected subscribers for Quantum BioPharma's (QNTM) private placement?
What is the hold period for securities issued in Quantum BioPharma's (QNTM) private placement?
How will Quantum BioPharma (QNTM) use the proceeds from the private placement?
